Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG NASDAQ:GYRE NASDAQ:MRSN NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$60.66$80.47$23.17▼$123.75$590.22M-5.53442,688 shs239,388 shsGYREGyre Therapeutics$6.25$6.80$5.44▼$9.42$606.44M1.989,045 shs85,723 shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsTLRYTilray Brands$4.73$5.81$3.51▼$23.20$551.28M1.883.41 million shs3.55 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+1.92%-1.48%-18.62%-15.30%+115.18%GYREGyre Therapeutics+2.80%+3.07%-0.16%-6.99%-24.97%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+226.65%TLRYTilray Brands-0.42%-7.62%-9.21%-23.83%+23.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$60.66$80.47$23.17▼$123.75$590.22M-5.53442,688 shs239,388 shsGYREGyre Therapeutics$6.25$6.80$5.44▼$9.42$606.44M1.989,045 shs85,723 shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsTLRYTilray Brands$4.73$5.81$3.51▼$23.20$551.28M1.883.41 million shs3.55 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+1.92%-1.48%-18.62%-15.30%+115.18%GYREGyre Therapeutics+2.80%+3.07%-0.16%-6.99%-24.97%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+226.65%TLRYTilray Brands-0.42%-7.62%-9.21%-23.83%+23.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 2.86Moderate Buy$143.83137.11% UpsideGYREGyre Therapeutics 2.00Hold$17.00172.00% UpsideMRSNMersana Therapeutics 1.88Reduce$25.92-10.88% DownsideTLRYTilray Brands 2.25Hold$11.50143.13% UpsideCurrent Analyst Ratings BreakdownLatest MRSN, TLRY, DRUG, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/13/2026DRUGBright Minds Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.004/2/2026TLRYTilray Brands ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$9.50 ➝ $9.004/2/2026TLRYTilray Brands Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.003/30/2026DRUGBright Minds Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$147.003/30/2026TLRYTilray Brands TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $7.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AGYREGyre Therapeutics$116.59M5.20$0.23 per share27.36$1.48 per share4.22MRSNMersana Therapeutics$33.18M4.38N/AN/A($1.92) per share-15.15TLRYTilray Brands$821.31M0.67$1.44 per share3.29$14.04 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)MRSNMersana Therapeutics-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/ATLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest MRSN, TLRY, DRUG, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A81.4781.47GYREGyre TherapeuticsN/A4.644.06MRSNMersana TherapeuticsN/A1.391.39TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%GYREGyre Therapeutics23.99%MRSNMersana Therapeutics93.92%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%GYREGyre Therapeutics9.50%MRSNMersana Therapeutics13.00%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableGYREGyre Therapeutics4097.03 million87.81 millionNo DataMRSNMersana Therapeutics1505.00 million4.35 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableMRSN, TLRY, DRUG, and GYRE HeadlinesRecent News About These CompaniesTilray Looks Cheap On The Surface, But Shareholders Still Need Proof2 hours ago | seekingalpha.comTop Cannabis Stocks To Keep An Eye On - June 18thJune 19 at 4:37 AM | americanbankingnews.comTilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from AnalystsJune 19 at 2:18 AM | americanbankingnews.comTilray Brands, Inc. (NASDAQ:TLRY) Given Average Rating of "Hold" by BrokeragesJune 19 at 2:17 AM | marketbeat.comTilray Brands, Inc.: BrewDog Turns Up Father's Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 18 at 10:10 PM | finanznachrichten.deTilray Brands, Inc.: Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 10:10 PM | finanznachrichten.deHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 12:09 PM | finance.yahoo.comBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 12:09 PM | finance.yahoo.comTilray takes Hi*Ball energy brand to UKJune 18 at 12:09 PM | just-drinks.comJBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:50 AM | financialpost.comFBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:30 AM | globenewswire.comHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 7:00 AM | globenewswire.comPromising Cannabis Stocks To Follow Now - June 17thJune 18 at 4:05 AM | americanbankingnews.comAltshuler Shaham Ltd Has $857,000 Stock Holdings in Tilray Brands, Inc. $TLRYJune 18 at 3:18 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% - What's Next?June 17 at 5:47 PM | marketbeat.com3 Marijuana Stocks Investors Can See Returns On Before The End Of The YearJune 17 at 1:26 PM | marijuanastocks.comMBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 9:16 AM | finance.yahoo.comBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 7:11 AM | financialpost.comFHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:38 PM | finance.yahoo.comHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:00 PM | zacks.comTilray Brands (NASDAQ:TLRY) Shares Down 2.6% - What's Next?June 16 at 5:46 PM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Best Growth Stocks for the Next 10 YearsBy Chris Markoch | May 31, 2026Biogen Stock Slides After Trial Miss, But Analysts Stay BullishBy Chris Markoch | May 22, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 2026MRSN, TLRY, DRUG, and GYRE Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$60.66 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$64.75 +4.09 (+6.74%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Gyre Therapeutics NASDAQ:GYRE$6.25 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.24 -0.01 (-0.24%) As of 06/18/2026 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mersana Therapeutics NASDAQ:MRSNMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Tilray Brands NASDAQ:TLRY$4.73 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.74 +0.00 (+0.11%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
